Hepion's Rencofilstat Combo Shows Anti-Tumor Activity In Nonclinical Liver Cancer Study

Hepion Pharmaceuticals Inc HEPA has announced the results of a nonclinical research study showing rencofilstat (CRV431) decreased liver tumor growth and extended mouse survival when combined with an anti-PD1 antibody. 

  • The effects were observed in fatty livers, suggesting that rencofilstat may increase the treatment potential of anti-PD1 treatment in human liver cancer.
  • Drug treatments began on Day 14 after HCC cell implantation when tumors were approximately 15% of their final, end-of-study size. 
  • Neither rencofilstat nor anti-PD1 administered alone altered the size of tumors at Day 28, nor the survival of the mice compared to vehicle treatment. 
  • Related: Hepion's CRV431 Shows Encouraging Safety Profile In Drug-Drug Interaction Study.
  • In contrast, the combination treatment of rencofilstat plus anti-PD1 decreased tumor size by 69% at Day 28 and increased median mouse survival time by 26%, compared to vehicle treatment. 
  • HCC model decreased tumor growth by 76% when tumorigenic cells were implanted into non-fatty livers but were not effective as monotherapies in fatty livers in the current study.
  • Price Action: HEPA shares are up 0.18% at $1.00 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!